Wang, Jing
Chen, Zhong-jin
Zhang, Ze-yi
Shen, Mei-ping
Zhao, Bo
Zhang, Wei
Zhang, Ye
Lei, Ji-gang
Ren, Cheng-jie
Chang, Jing
Xu, Cui-li
Li, Meng
Pi, Yang-yang
Lu, Tian-lun
Dai, Cheng-xiang
Li, Su-ke
Li, Ping http://orcid.org/0000-0001-9713-3915
Article History
Received: 20 February 2023
Accepted: 25 March 2024
First Online: 2 April 2024
Declarations
:
: Project 1: (1) Title of the approved project: Toxicity study of intratracheal administrated RE0101 in SD rats by 4 weeks of repeated endotracheal injection and 4 weeks of recovery; (2) Name of the institutional approval committee or unit: Institutional Animal Care and Use Committee of Shanghai Innostar Biotechnology Co., Ltd.; (3) Approval number: 2020–464; (4) Date of approval:17th December 2020. Project 2: (1) Title of the approved project: Therapeutic effects of RE0101 on LPS induced acute lung injury in rats; (2) Name of the institutional approval committee or unit: Institutional Animal Care and Use Committee of Tianjin Tiancheng Drug Assessment & Research Co., Ltd.; (3) Approval number: 2205-PDET-2; (4) Date of approval: 25th April 2022.
: Not applicable.
: Ping Li, Su-ke Li, Jing Wang, Ji-gang Lei and Cheng-xiang Dai are inventors on the patent application ‘Atomized inhalation formulation containing human cell-derived extracellular vesicles, preparation method and use thereof’ (WO2021/180237). All other authors declare no potential conflicts of interests.